Program: Special-Interest Sessions
Session: ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
Session: ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
Monday, December 9, 2024, 4:30 PM-6:00 PM
Disclosures: Lanzkron: HRSA: Research Funding; PCORI: Research Funding; CSL-Behring: Research Funding; GBT: Research Funding; Takeda: Research Funding; GMI: Consultancy; Agios: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy; Merck: Consultancy; Pfizer: Consultancy; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Bluebird BIo: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: Stock in Family trust; Teva: Other: Stock in Family trust.